Table 1.
The clinicopathologic features of the 8 xenograft donor patients.
| MDA PCa Cell Line Designationa | ||||||||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| Feature | 79 | 117 | 130 | 144 | 146 | 155 | 170 | 180 |
| At presentation | ||||||||
|
| ||||||||
| Age (years) | 61 | 60 | 65 | 68 | 74 | 72 | 63 | 72 |
| PSA (ng/ml) | 65 | 99 | 24 | 4.6 | 10.7 | 1.7 | 19.8 | 53 |
| NBx morphology | AdCa | AdCa | AdCa | AdCa | AdCa | SCC | AdCa | AdCa |
| Gleason Score | 4+4 | 5+5 | 4+4 | 4+3 | 3+4 | - | 9 | 9 |
|
| ||||||||
| Prior treatment | ||||||||
|
| ||||||||
| Androgen ablation | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Radiation | Yes | No | Yes | Yes | Yes | No | No | No |
| Chemotherapy | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
|
| ||||||||
| At surgery | ||||||||
|
| ||||||||
| Age (years) | 67 | 64 | 76 | 72 | 78 | 72 | 64 | 74 |
| Procedure | PE | CPX | CPX | PE | CPX | PE | CXPX | CXPX |
| Tissue morphology | AdCa | AdCa with NE diff | AdCa | Mixed AdCa SCPC and LCNEC | Mixed AdCa and SCPC | SCPC | AdCa | AdCa |
| GleasonScore | 5+4 | 4+5 | 4+5 | 4+4 | 5+4 | - | 5+4 | 5+4 |
| Pathologicstage | T4Nx | T4N1 | T4N0 | T4N1 | T4N1 | T4N0 | T4N1 | T4N1 |
|
| ||||||||
| Overall survival (years) | 13.3 | 5.3 | 17.6 | 4.8 | 6.2 | 0.6 | 2.5 | 3.8 |
|
| ||||||||
| RE | −1b PR | PR | −4 PR | −10 BL | −2 BL | −1 PR | −11 BL | |
| −9 PR | −6 PR | −12b BL | −9 BL | −4 PR | −14 BL | |||
| −9 PR | −17 BL | −12 BL | - 18 BL | |||||
| Site of tissue collection | −11 BL | −20 BL | −16 PR | - 21 BL | ||||
| −13 BL | -30 SV | |||||||
| −17 BL | ||||||||
| −20 RE | ||||||||
| −23 RE | ||||||||
a
Numbers indicated by “−” are cell sublines.
b
These xenografts were unstable and were not developed any further.
Abbreviations: PSA, prostate-specific antigen; NBx, need lebiopsy; AdCa, adenocarcinoma; SCC, small-cellcarcinoma; PE, pelvic exenteration; CPX, cystoprostatectomy; CXPX, cystoprostatectomy; NE diff, neuroendocrine differentiation; SCPC, small-cell prostate carcinoma; LCNEC, large-cell NE carcinoma; RE, rectal wall; PR, prostate; BL, bladder wall; SV, seminal vesicles.